ULTRALIFE CORP
For the period ended Mar 31, 2024. Filed Apr 25, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed Apr 25, 2024
Contents
Item 1. Consolidated Financial Statements (unaudited)
| Consolidated Balance Sheets as of March 31, 2024 and December 31, 2023 | 1 | |
| Consolidated Statements of Income (Loss) and Comprehensive Income (Loss) for the Three-Month Periods Ended March 31, 2024 and March 31, 2023 | 2 | |
| Consolidated Statements of Cash Flows for the Three-Month Periods Ended March 31, 2024 and March 31, 2023 | 3 | |
| Consolidated Statements of Changes in Stockholders’ Equity for the Three-Month Periods Ended March 31, 2024 and March 31, 2023 | 4 | |
| Notes to Consolidated Financial Statements | 5 | |
| Item 2. | Management’s Discussion and Analysis of Financial Condition and Results of Operations | 15 |
|---|---|---|
| Item 4. | Controls and Procedures | 23 |
| PART II. | OTHER INFORMATION | |
| Item 6. | Exhibits | 24 |
| Signatures | 25 |
PART I. FINANCIAL INFORMATION
ULTRALIFE CORPORATION AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
(In Thousands except share amounts)
(Unaudited)
| March 31, 2024 | December 31, 2023 | |
|---|---|---|
| ASSETS | ||
| Current assets: | ||
| Cash | $10,099 | $10,278 |
| Trade accounts receivable, net of allowance for expected credit losses of $300 and $300, respectively | 35,278 | 31,761 |
| Inventories, net | 43,821 | 42,215 |
| Prepaid expenses and other current assets | 5,104 | 5,949 |
| Total current assets | 94,302 | 90,203 |
| Property, plant and equipment, net | 20,670 | 21,117 |
| Goodwill | 37,499 | 37,571 |
| Other intangible assets, net | 14,867 | 15,107 |
| Deferred income taxes, net | 9,873 | 10,567 |
| Other noncurrent assets | 3,340 | 3,711 |
| Total assets | $180,551 | $178,276 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||
| Current liabilities: | ||
| Accounts payable | $13,315 | $11,336 |
| Current portion of long-term debt | 2,000 | 2,000 |
| Accrued compensation and related benefits | 2,013 | 3,115 |
| Accrued expenses and other current liabilities | 6,048 | 7,279 |
| Total current liabilities | 23,376 | 23,730 |
| Long-term debt | 23,140 | 23,624 |
| Deferred income taxes | 1,675 | 1,714 |
| Other noncurrent liabilities | 3,415 | 3,781 |
| Total liabilities | 51,606 | 52,849 |
| Commitments and contingencies (Note 8) | ||
| Stockholders’ equity: | ||
| Preferred stock – par value $.10 per share; authorized 1,000,000 shares; none issued | - | - |
| Common stock – par value $.10 per share; authorized 40,000,000 shares; issued – 20,887,446 shares at March 31, 2024 and 20,783,607 shares at December 31, 2023; outstanding – 16,451,332 shares at March 31, 2024 and 16,347,493 shares at December 31, 2023 | 2,089 | 2,078 |
| Capital in excess of par value | 189,995 | 189,160 |
| Accumulated deficit | (37,863) | (40,754) |
| Accumulated other comprehensive loss | (3,892) | (3,660) |
| Treasury stock - at cost; 4,436,114 shares at March 31, 2024 and 4,436,114 shares at December 31, 2023 | (21,492) | (21,492) |
| Total Ultralife Corporation equity | 128,837 | 125,332 |
| Non-controlling interest | 108 | 95 |
| Total stockholders’ equity | 128,945 | 125,427 |
| Total liabilities and stockholders’ equity | 180,551 | $178,276 |
ULTRALIFE CORPORATION AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF INCOME (LOSS) AND COMPREHENSIVE INCOME (LOSS) (In Thousands except per share amounts) (Unaudited)
| Three-month period ended | ||
|---|---|---|
| March 31, 2024 | March 31, 2023 | |
| Revenues | $41,927 | $31,916 |
| Cost of products sold | 30,457 | 24,480 |
| Gross profit | 11,470 | 7,436 |
| Operating expenses: | ||
| Research and development | 1,756 | 2,032 |
| Selling, general and administrative | 5,651 | 5,378 |
| Total operating expenses | 7,407 | 7,410 |
| Operating income | 4,063 | 26 |
| Other (expense) income: | ||
| Interest and financing expense | (520) | (424) |
| Miscellaneous income (expense) | 64 | (70) |
| Total other expense | (456) | (494) |
| Income (loss) before income taxes | 3,607 | (468) |
| Income tax provision (benefit) | 703 | (133) |
| Net income (loss) | 2,904 | (335) |
| Net income attributable to non-controlling interest | (13) | (11) |
| Net income (loss) attributable to Ultralife Corporation | 2,891 | (346) |
| Other comprehensive (loss) income: | ||
| Foreign currency translation adjustments | (232) | 197 |
| Comprehensive income (loss) attributable to Ultralife Corporation | $2,659 | $(149) |
| Net income (loss) per share attributable to Ultralife common stockholders – basic | $.18 | $(.02) |
| Net income (loss) per share attributable to Ultralife common stockholders – diluted | $.18 | $(.02) |
| Weighted average shares outstanding – basic | 16,396 | 16,135 |
| Potential common shares | 122 | - |
| Weighted average shares outstanding - diluted | 16,518 | 16,135 |
ULTRALIFE CORPORATION AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF CASH FLOWS (Dollars in Thousands) (Unaudited)
| Three-month period ended | ||
|---|---|---|
| March 31, 2024 | March 31, 2023 | |
| OPERATING ACTIVITIES: | ||
| Net income (loss) | $2,904 | $(335) |
| Adjustments to reconcile net income (loss) to net cash used in operating activities: | ||
| Depreciation | 740 | 762 |
| Amortization of intangible assets | 228 | 209 |
| Amortization of financing fees | 16 | 16 |
| Stock-based compensation | 161 | 139 |
| Deferred income taxes | 650 | (390) |
| Changes in operating assets and liabilities: | ||
| Accounts receivable | (3,562) | 3,365 |
| Inventories | (1,699) | (6,026) |
| Prepaid expenses and other assets | 1,102 | 639 |
| Accounts payable and other liabilities | (621) | 256 |
| Net cash used in operating activities | (81) | (1,365) |
| INVESTING ACTIVITIES: | ||
| Purchases of property, plant and equipment | (372) | (497) |
| Net cash used in investing activities | (372) | (497) |
| FINANCING ACTIVITIES: | ||
| Borrowings on revolving credit facility | - | 2,300 |
| Payments on term loan facility | (500) | (500) |
| Proceeds from exercise of stock options | 685 | - |
| Net cash provided by financing activities | 185 | 1,800 |
| Effect of exchange rate changes on cash | 89 | (46) |
| DECREASE IN CASH | (179) | (108) |
| Cash, Beginning of period | 10,278 | 5,713 |
| Cash, End of period | $10,099 | $5,605 |
The accompanying notes are an integral part of these consolidated financial statements.
ULTRALIFE CORPORATION AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY
(In Thousands except share amounts) (Unaudited)
| Capital · Accumulated | ||||||||
|---|---|---|---|---|---|---|---|---|
| Common Stock · in Excess · Other · Non- | ||||||||
| Number of · of Par · Comprehensive · Accumulated · Treasury · Controlling | ||||||||
| Shares | Amount | Value | Income (Loss) | Deficit | Stock | Interest | Total | |
| Balance – December 31, 2022 | 20,570,710 | $2,057 | $187,405 | $(3,750) | $(47,951) | $(21,484) | $126 | $116,403 |
| Net loss | (346) | 11 | (335) | |||||
| Stock option exercises | - | |||||||
| Stock-based compensation – stock options | 138 | 138 | ||||||
| Stock-based compensation – restricted stock | 1 | 1 | ||||||
| Foreign currency translation adjustments adjustments | 197 | 197 | ||||||
| Balance – March 31, 2023 | 20,570,710 | $2,057 | $187,544 | $(3,553) | $(48,297) | $(21,484) | $137 | $116,404 |
| Balance – December 31, 2023 | 20,783,607 | $2,078 | $189,160 | $(3,660) | $(40,754) | $(21,492) | $95 | $125,427 |
| Net income | 2,891 | 13 | 2,904 | |||||
| Stock option exercises | 103,839 | 11 | 674 | 685 | ||||
| Stock-based compensation – stock options | 156 | 156 | ||||||
| Stock-based compensation – restricted stock | 5 | 5 | ||||||
| Foreign currency translation adjustments adjustments | (232) | (232) | ||||||
| Balance – March 31, 2024 | 20,887,446 | $2,089 | $189,995 | $(3,892) | $(37,863) | $(21,492) | $108 | $128,945 |
ULTRALIFE CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(In thousands except share and per share amounts)
(Unaudited)
| 1. | BASIS OF PRESENTATION |
The accompanying unaudited consolidated financial statements of Ultralife Corporation and its subsidiaries (the “Company” or “Ultralife”) have been prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”) for interim financial information and with the instructions to Rule 8-03 of Regulation S-X. Accordingly, they do not include all the information and notes for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals and adjustments) considered necessary for a fair presentation of the consolidated financial statements have been included. Results for interim periods should not be considered indicative of results to be expected for a full year. Reference should be made to the consolidated financial statements and related notes thereto contained in our Form 10-K for the year ended December 31, 2023.
The December 31, 2023 consolidated balance sheet information referenced herein was derived from audited financial statements but does not include all disclosures required by GAAP.
Certain items previously reported in specific financial statement captions have been reclassified to conform to the current presentation.
Recently Adopted Accounting Guidance
None.
Recent Accounting Guidance Not Yet Adopted
In December 2023, the Financial Accounting Standards Board (“FASB”) issued ASU 2023-09 "Income Taxes (Topics 740): Improvements to Income Tax Disclosures" to expand the disclosure requirements for income taxes, specifically related to the rate reconciliation and income taxes paid. ASU 2023-09 is effective for our annual periods beginning January 1, 2025, with early adoption permitted. We are currently evaluating the potential effect that the updated standard will have on our financial statement disclosures.
| 2. | DEBT |
On December 13, 2021, Ultralife, Southwest Electronic Energy Corporation, a Texas corporation and wholly owned subsidiary of Ultralife (“SWE”), CLB, INC., a Texas corporation and wholly owned subsidiary of SWE (“CLB”), Ultralife Excell Holding Corp., a Delaware corporation and wholly owned subsidiary of Ultralife (“UEHC”), Ultralife Canada Holding Corp., a Delaware corporation and wholly owned subsidiary of UEHC (“UCHC”), and Excell Battery Corporation USA, a Texas corporation and wholly owned subsidiary of UEHC (“Excell USA”), as borrowers, entered into the Second Amendment Agreement with KeyBank National Association (“KeyBank” or the “Bank”), as lender and administrative agent, to amend the Credit and Security Agreement dated May 31, 2017 as amended by the First Amendment Agreement by and among Ultralife, SWE, CLB and KeyBank dated May 1, 2019 (the “Credit Agreement”). On November 28, 2022, Ultralife, SWE, CLB, UEHC, UCHC, Excell USA, and Excell Battery Canada ULC, a British Columbia unlimited liability corporation and wholly owned subsidiary of UCHC (“Excell Canada”), entered into that certain Third Amendment Agreement with KeyBank, to further amend the Credit Agreement to, among other things, facilitate the joinder of Excell Canada as a guarantor under the Credit Agreement and to replace the LIBOR benchmark thereunder with SOFR (the “Third Amendment Agreement”, and together with the Second Amendment Agreement and the Credit Agreement, the “Amended Credit Agreement”).
The Amended Credit Agreement, among other things, provides for a 5-year, $10,000 senior secured term loan (the “Term Loan Facility”) and extends the term of the $30,000 senior secured revolving credit facility (the “Revolving Credit Facility”, and together with the Term Loan Facility, the “Amended Credit Facilities”) through May 30, 2025. Up to six months prior to May 30, 2025, the Revolving Credit Facility may be increased to $50,000 with the Bank’s concurrence.
As of March 31, 2024, the Company had $5,667 outstanding principal on the Term Loan Facility, $2,000 of which is included in current portion of long-term debt on the balance sheet, and $19,580 outstanding on the Revolving Credit Facility. As of March 31, 2024, total unamortized debt issuance costs of $107, including placement, renewal and legal fees associated with the Amended Credit Agreement, are classified as a reduction of long-term debt on the balance sheet. Debt issuance costs are amortized to interest expense over the term of the Amended Credit Facilities.
The remaining availability under the Revolving Credit Facility is subject to certain borrowing base limits based on trade receivables and inventories.
The Company is required to repay the borrowings under the Term Loan Facility in equal consecutive monthly payments commencing on February 1, 2022, in arrears, together with applicable interest. All unpaid principal and accrued and unpaid interest with respect to the Term Loan Facility is due and payable in full on January 1, 2027. All unpaid principal and accrued and unpaid interest with respect to the Revolving Credit Facility is due and payable in full on May 30, 2025. The Company may voluntarily prepay principal amounts outstanding at any time subject to certain restrictions.
In addition to the customary affirmative and negative covenants, the Company must maintain a consolidated senior leverage ratio, as defined in the Amended Credit Agreement, of equal to or less than 3.5 to 1.0 for the fiscal quarters ending December 31, 2022 and March 31, 2023, and equal to or less than 3.0 to 1.0 for the fiscal quarters ending June 30, 2023 and thereafter. The Company was in full compliance with its covenants under the Amended Credit Agreement as of March 31, 2024.
Borrowings under the Amended Credit Facilities are secured by substantially all the assets of the Company and its subsidiaries.
Upon the effectiveness of the Third Amendment Agreement, interest accrues on outstanding indebtedness under the Amended Credit Facilities at the Daily Simple SOFR Rate, plus an index spread adjustment of 0.10%, plus the applicable margin. The applicable margin ranges from 185 to 215 basis points and is determined based on the Company’s senior leverage ratio.
The Company must pay a fee of 0.15% to 0.25% based on the average daily unused availability under the Revolving Credit Facility.
Payments must be made by the Company to the extent borrowings exceed the maximum amount then permitted to be drawn on the Amended Credit Facilities and from the proceeds of certain transactions. Upon the occurrence of an event of default, the outstanding obligations may be accelerated, and the Bank will have other customary remedies including resort to the security interest the Company provided to the Bank.
| 3. | EARNINGS PER SHARE |
Basic earnings (loss) per share (“EPS”) is computed by dividing net income (loss) attributable to Ultralife Corporation by the weighted average shares outstanding during the period. Diluted EPS includes the dilutive effect of securities, if any, and is calculated using the treasury stock method.
For the three-month period ended March 31, 2024, there were 539,358 outstanding stock options and 5,229 unvested restricted stock awards included in the calculation of diluted weighted average shares outstanding, as such securities were dilutive, resulting in 122,515 potential common shares included in the calculation of diluted EPS. There were 524,502 outstanding stock options for the three-month period ended March 31, 2024 not included in EPS as the effect would be anti-dilutive.
For the comparable three-month period ended March 31, 2023, there wereno outstanding awards included in the calculation of diluted weighted average shares outstanding andno potential common shares included in the calculation of diluted EPS, as no securities were dilutive. There were 1,420,611 outstanding stock options and 2,500 unvested restricted stock awards not included in the calculation of diluted EPS for the three-month period ended March 31, 2023, as the effect would be antidilutive.
| 4. | SUPPLEMENTAL BALANCE SHEET INFORMATION |
Fair Value Measurements and Disclosures
The fair value of financial instruments approximated their carrying values at March 31, 2024 and December 31, 2023. The fair value of cash, accounts receivable, accounts payable, accrued liabilities, and the current portion of long-term debt approximates carrying value due to the short-term nature of these instruments.
Cash
The composition of the Company’s cash was as follows:
| March 31, | December 31, | |
|---|---|---|
| 2024 | 2023 | |
| Cash | $10,099 | $10,196 |
| Restricted cash | - | 82 |
| Total | $10,099 | $10,278 |
As December 31, 2023, restricted cash of $82 represented euro-denominated deposits withheld by the Dutch tax authorities and third-party VAT representatives in connection with a previously utilized logistics arrangement in the Netherlands. During the quarter ended March 31, 2024, the deposits were returned to the Company and no longer restricted. As of March 31, 2024, there was no cash classified as restricted cash. Restricted cash as of December 31, 2023 is included as a component of the cash balance for purposes of the consolidated statements of cash flows.
Inventories, Net
Inventories are stated at the lower of cost or net realizable value, net of obsolescence reserves, with cost determined under the first-in, first-out (FIFO) method. The composition of inventories, net was:
| March 31, | December 31, | |
|---|---|---|
| 2024 | 2023 | |
| Raw materials | $30,168 | $29,098 |
| Work in process | 3,593 | 3,187 |
| Finished goods | 10,060 | 9,930 |
| Total | $43,821 | $42,215 |
Property, Plant and Equipment, Net
Major classes of property, plant and equipment consisted of the following:
| March 31, | December 31, | |
|---|---|---|
| 2024 | 2023 | |
| Land | $1,273 | $1,273 |
| Buildings and leasehold improvements | 16,007 | 15,998 |
| Machinery and equipment | 57,427 | 57,584 |
| Furniture and fixtures | 2,818 | 2,845 |
| Computer hardware and software | 7,770 | 7,868 |
| Construction in process | 1,695 | 2,033 |
| 86,990 | 87,601 | |
| Less: Accumulated depreciation | (66,320) | (66,484) |
| Property, plant and equipment, net | $20,670 | $21,117 |
Depreciation expense for property, plant and equipment was $740 and $762 for the three-month periods ended March 31, 2024 and March 31, 2023, respectively.
Goodwill
The following table summarizes the goodwill activity by segment for the three-month period ended March 31, 2024.
| Battery & Energy · Communications | |||
|---|---|---|---|
| Products | Systems | Total | |
| Balance – December 31, 2023 | $26,078 | $11,493 | $37,571 |
| Effect of foreign currency translation | (72) | - | (72) |
| Balance – March 31, 2024 | $26,006 | $11,493 | $37,499 |
Other Intangible Assets, Net
The composition of other intangible assets was:
| Accumulated | |||
|---|---|---|---|
| Cost | Amortization | Net | |
| Customer relationships | $13,072 | $6,796 | $6,276 |
| Patents and technology | 5,597 | 5,344 | 253 |
| Trade names | 4,645 | 673 | 3,972 |
| Trademarks | 3,400 | - | 3,400 |
| Other | 1,500 | 534 | 966 |
| Total other intangible assets | $28,214 | $13,347 | $14,867 |
| Accumulated | |||
|---|---|---|---|
| Cost | Amortization | Net | |
| Customer relationships | $13,092 | $6,656 | $6,436 |
| Patents and technology | 5,606 | 5,322 | 284 |
| Trade names | 4,647 | 647 | 4,000 |
| Trademarks | 3,402 | - | 3,402 |
| Other | 1,500 | 515 | 985 |
| Total other intangible assets | $28,247 | $13,140 | $15,107 |
The change in the cost of total intangible assets from December 31, 2023 to March 31, 2024 is the effect of foreign currency translations.
Amortization expense for intangible assets was $228 and $209 for the three-month periods ended March 31, 2024 and March 31, 2023, respectively. Amortization included in selling, general and administrative expenses was $203 and $185 for the three-month periods ended March 31, 2024 and March 31, 2023, respectively. Amortization included in research and development expenses was $25 and $24 for the three-month periods ended March 31, 2024 and March 31, 2023, respectively.
| 5. | STOCK-BASED COMPENSATION |
We recorded non-cash stock compensation expense in each period as follows:
| Three-month period ended | ||
|---|---|---|
| March 31, | March 31, | |
| 2024 | 2023 | |
| Stock options | $156 | $138 |
| Restricted stock grants | 5 | 1 |
| Total | $161 | $139 |
We have stock options outstanding from various stock-based employee compensation plans for which we record compensation cost relating to share-based payment transactions in our financial statements. As of March 31, 2024, there was $699 of total unrecognized compensation cost related to outstanding stock options, which is expected to be recognized over a weighted average period of 1.3 years.
The following table summarizes stock option activity for the three-month period ended March 31, 2024:
| Number of Shares | Weighted Average Exercise Price | Weighted Average Remaining Contractual Term (years) | Aggregate Intrinsic Value | |
|---|---|---|---|---|
| Outstanding at January 1, 2024 | 1,250,595 | $7.10 | ||
| Granted | 3,460 | 6.84 | ||
| Exercised | (103,839) | 6.60 | ||
| Forfeited or expired | (86,356) | $8.96 | ||
| Outstanding at March 31, 2024 | 1,063,860 | $7.00 | 4.22 | $2,258 |
| Vested and expected to vest at March 31, 2024 | 964,552 | $7.07 | 4.06 | $1,987 |
| Exercisable at March 31, 2024 | 604,537 | $7.50 | 2.92 | $1,018 |
Cash received from stock option exercises under our stock-based compensation plans for the three-month periods ended March 31, 2024 and March 31, 2023 was $685 and $0, respectively.
Restricted stock awards vest in equal annual installments over three(3) years. Unrecognized compensation cost related to unvested restricted shares at March 31, 2024 and March 31, 2023, respectively, was $31 and $2.
| 6. | INCOME TAXES |
Our effective tax rate for the three-month periods ended March 31, 2024 and March 31, 2023 was 19.5% and 28.4%, respectively. The period-over-period change was primarily attributable to the geographic mix of our operating results.
As of December 31, 2023, we have domestic net operating loss (“NOL”) carryforwards of $27,200, which expire 2031 through 2035, and domestic tax credits of $2,900, which expire 2028 through 2043, available to reduce future taxable income. As of March 31, 2024, management has concluded it is more likely than not that these domestic NOL and credit carryforwards will be fully utilized.
As of March 31, 2024, for certain past operations in the U.K., we continue to report a valuation allowance for NOL carryforwards of approximately $9,800, nearly all of which can be carried forward indefinitely. Utilization of the net operating losses may be limited due to the change in the past U.K. operation and cannot currently be used to reduce taxable income at our other U.K. subsidiary, Accutronics Ltd. There are no other deferred tax assets related to the past U.K. operations.
As of March 31, 2024, we havenot recognized a valuation allowance against our other foreign deferred tax assets, as realization is considered to be more likely than not.
As of March 31, 2024, the Company maintains its assertion that all foreign earnings will be indefinitely reinvested in those operations, other than earnings generated in the U.K.
There wereno unrecognized tax benefits related to uncertain tax positions at March 31, 2024 and December 31, 2023.
As a result of our operations, we file income tax returns in various jurisdictions including U.S. federal, U.S. state and foreign jurisdictions. We are routinely subject to examination by taxing authorities in these various jurisdictions. Our U.S. tax matters for 2020 thru 2022 remain subject to IRS examination. Our U.S. tax matters for 2001-2002,2005-2007, 2009, and 2011-2015 also remain subject to IRS examination due to the remaining availability of net operating loss carryforwards generated in those years. Our U.S. tax matters for 2013 thru 2022 remain subject to examination by various state and local tax jurisdictions. Our tax matters for the years 2013 thru 2022 remain subject to examination by the respective foreign tax jurisdiction authorities.
| 7. | OPERATING LEASES |
The Company has operating leases predominantly for operating facilities. As of March 31, 2024, the remaining lease terms on our operating leases range from approximately less than one (1) year to eight (8) years. Lease terms include renewal options reasonably certain of exercise. There is no transfer of title or option to purchase the leased assets upon expiration. There are no residual value guarantees or material restrictive covenants.
The components of lease expense for the current and prior-year comparative periods were as follows:
| Three-month period ended March 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Operating lease cost | $262 | $241 |
| Variable lease cost | 28 | 28 |
| Total lease cost | $290 | $269 |
Supplemental cash flow information related to leases was as follows:
| Three-month period ended March 31, | ||||
|---|---|---|---|---|
| 2024 · 2023 | ||||
| Cash paid for amounts included in the measurement of lease liabilities: | ||||
| Operating cash flows from operating leases | $265 | $226 | ||
| Right-of-use assets obtained in exchange for lease liabilities: | $ | - | $ | - |
Supplemental consolidated balance sheet information related to leases was as follows:
| Balance sheet classification · March 31, 2024 · December 31, 2023 | |||||
|---|---|---|---|---|---|
| Assets: | |||||
| Operating lease right-of-use asset | Other noncurrent assets | $3,177 | $3,589 | ||
| Liabilities: | |||||
| Current operating lease liability | Accrued expenses and other current liabilities | $780 | $894 | ||
| Operating lease liability, net of current portion | Other noncurrent liabilities | 2,350 | 2,644 | ||
| Total operating lease liability | $3,130 | $3,538 | |||
| Weighted-average remaining lease term (years) | 5.2 | 5.3 | |||
| Weighted-average discount rate | 6.3% | 4.5% | |||
Future minimum lease payments as of March 31, 2024 are as follows:
| Maturity of operating lease liabilities | |
|---|---|
| 2024 | $620 |
| 2025 | 691 |
| 2026 | 618 |
| 2027 | 639 |
| 2028 | 642 |
| Thereafter | 458 |
| Total lease payments | 3,668 |
| Less: Imputed interest | (538) |
| Present value of remaining lease payments | $3,130 |
| 8. | COMMITMENTS AND CONTINGENCIES |
Purchase Commitments
As of March 31, 2024, we have made commitments to purchase approximately $330 of production machinery and equipment.
Product Warranties
We estimate future warranty costs to be incurred for product failure rates, material usage and service costs in the development of our warranty obligations. Estimated future costs are based on actual past experience and are generally estimated as a percentage of sales over the warranty period. Changes in our product warranty liability during the first three months of 2024 and 2023 were as follows:
| Three-month period ended March 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Accrued warranty obligations – beginning | $547 | $323 |
| Accruals for warranties issued | 141 | 84 |
| Settlements made | (49) | (21) |
| Accrued warranty obligations – ending | $639 | $386 |
Contingencies and Legal Matters
We are subject to legal proceedings and claims that arise from time to time in the normal course of business. We believe that the final disposition of any such matters will not have a material adverse effect on the Company’s financial position, results of operations or cash flows. However, recognizing that legal matters are subject to inherent uncertainties, there exists the possibility that ultimate resolution of these matters could have a material adverse impact on the Company’s financial position, results of operations or cash flows. We are not aware of any such situations at this time.
| 9. | REVENUE RECOGNITION |
Revenues are generated from the sale of products. Performance obligations are met and revenue is recognized upon transfer of control to the customer, which is generally upon shipment. When contract terms require transfer of control upon delivery at a customer’s location, revenue is recognized on the date of delivery. For products shipped under vendor-managed inventory arrangements, revenue is recognized and billed when the product is consumed by the customer, at which point control has transferred and there are no further obligations by the Company. Revenue is measured as the amount of consideration we expect to receive in exchange for shipped product. Sales, value-added and other taxes billed and collected from customers are excluded from revenue. Customers, including distributors, do not have a general right of return.
Separately priced extended warranty contracts are offered on certain Communications Systems products for a duration of up to eight (8) years. Extended warranties are treated as separate performance obligations and recognized to revenue evenly over the term of the respective contract. Revenue not yet recognized on extended warranty contracts is recorded as deferred revenue on the consolidated balance sheet. For the quarter ended March 31, 2024, revenue recognized on extended warranties was $72.
As of March 31, 2024, there was deferred revenue on extended warranty contracts of $1,335, comprised of $287 expected to be recognized as revenue within one (1) year and classified as accrued expenses and other current liabilities on our consolidated balance sheet, and $1,048 expected to be recognized as revenue over the remaining duration of the respective contracts and classified as other noncurrent liabilities on our consolidated balance sheet.
As of December 31, 2023, there was deferred revenue on extended warranty contracts of $1,407, comprised of $287 expected to be recognized as revenue within one (1) year and classified as accrued expenses and other current liabilities on our consolidated balance sheet, and $1,120 expected to be recognized as revenue evenly over the remaining duration of the respective contracts and classified as other noncurrent liabilities on our consolidated balance sheet.
As of March 31, 2024 and December 31, 2023, the Company had no other unsatisfied performance obligations for contracts with an original expected duration of greater than one year. Pursuant to Topic 606, we have applied the practical expedient with respect to disclosure of the deferral and future expected timing of revenue recognition for transaction price allocated to remaining performance obligations.
| 10. | BUSINESS SEGMENT INFORMATION |
We report our results intwo operating segments: Battery & Energy Products and Communications Systems. The Battery & Energy Products segment includes Lithium 9-volt, cylindrical and various other non-rechargeable batteries, in addition to rechargeable batteries, uninterruptable power supplies, charging systems and accessories. The Communications Systems segment includes RF amplifiers, power supplies, cable and connector assemblies, amplified speakers, equipment mounts, case equipment, man-portable systems, integrated communication systems for fixed or vehicle applications and communications and electronics systems design. We believe that reporting performance at the gross profit level is the best indicator of segment performance.
Three-month period ended March 31, 2024:
| Battery & Energy Products · Communications Systems · Corporate · Total | |||||
|---|---|---|---|---|---|
| Revenues | $34,989 | $6,938 | $ | - | $41,927 |
| Segment contribution | 8,986 | 2,484 | (7,407) | 4,063 | |
| Other expense | (456) | (456) | |||
| Tax provision | (703) | (703) | |||
| Non-controlling interest | (13) | (13) | |||
| Net income attributable to Ultralife Corporation | $2,891 | ||||
Three-month period ended March 31, 2023:
| Battery & Energy Products · Communications Systems · Corporate · Total | |||||
|---|---|---|---|---|---|
| Revenues | $28,470 | $3,446 | $ | - | $31,916 |
| Segment contribution | 6,512 | 924 | (7,410) | 26 | |
| Other expense | (494) | (494) | |||
| Tax benefit | 133 | 133 | |||
| Non-controlling interest | (11) | (11) | |||
| Net loss attributable to Ultralife Corporation | $(346) | ||||
The following tables disaggregate our business segment revenues by major source and geography.
Commercial and Government/Defense Revenue Information:
Three-month period ended March 31, 2024:
| Total Revenue | Commercial | Government/ Defense | |
|---|---|---|---|
| Battery & Energy Products | $34,989 | $24,140 | $10,849 |
| Communications Systems | 6,938 | - | 6,938 |
| Total | $41,927 | $24,140 | $17,787 |
| 58% | 42% | ||
Three-month period ended March 31, 2023:
| Total Revenue | Commercial | Government/ Defense | |
|---|---|---|---|
| Battery & Energy Products | $28,470 | $22,219 | $6,251 |
| Communications Systems | 3,446 | - | 3,446 |
| Total | $31,916 | $22,219 | $9,697 |
| 70% | 30% | ||
U.S. and Non-U.S. Revenue Information 1:
Three-month period ended March 31, 2024:
| Total Revenue | United States | Non-United States | |
|---|---|---|---|
| Battery & Energy Products | $34,989 | $19,603 | $15,386 |
| Communications Systems | 6,938 | 4,858 | 2,080 |
| Total | $41,927 | $24,461 | $17,466 |
| 58% | 42% | ||
Three-month period ended March 31, 2023:
| Total Revenue | United States | Non-United States | |
|---|---|---|---|
| Battery & Energy Products | $28,470 | $13,768 | $14,702 |
| Communications Systems | 3,446 | 2,877 | 569 |
| Total | $31,916 | $16,645 | $15,271 |
| 52% | 48% | ||
1 Sales classified to U.S. include shipments to U.S.-based prime contractors which in some cases may serve non-U.S. projects.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.